TXA is effective and safe for reducing blood loss and transfusion in TKA patients .
Is tranexamic acid clinically effective and safe to prevent blood loss in total knee arthroplasty? A meta-analysis of 34 randomized controlled trials
Eur J Orthop Surg Traumatol. 2015 Apr;25(3):525-4134 randomized controlled trials (2,594 patients) were used in this meta-analysis analyzing the safety and efficacy of tranexamic acid (TXA) in patients undergoing primary total knee arthroplasty (TKA). Pooled results demonstrated intravenous (IV) and intraarticular (IA) use of TXA significantly reduced total blood loss, postoperative blood loss, hemoglobin (Hb) loss, and blood transfusion without increasing the risk of deep vein thrombosis (DVT) or other adverse effects.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
